
macmonagail@gmail.com
For verified host and producer emails, sign up to view.
Episodes: 688
Frequency: Weekly
Rating: 4.4/5.0
Estimated listeners: 1k-10k
Gender skew: Unknown
Location: USA
macmonagail@gmail.com
For verified host and producer emails, sign up to view.
Moira Gunn - Biomedical engineer and technology journalist known for covering biotechnology, healthcare, science, and innovation.
Jeremy Levin - Biotechnology’s Strategic Importance, Industry Challenges, Pandemics, Funding, Politics, And Healthcare Innovation.
Toby Stuart - Social Status, Unequal Access To Opportunities, Entrepreneurship, And Winner-take-most Markets.
Steve Harr - Engineering Insulin-producing Cells For People With Type 1 Diabetes And Developing Alternatives To Immunosuppressive Treatment.
Eric Ries - Corporate Integrity, Organizational Failure, And How Companies Sustain Strong Cultures And Performance.
Episode 684: Episode 26-27 Biotech in the Balance
July 07, 2026
On this week’s Tech Nation, Moira speaks with Physician and Entrepreneur, Dr. Jeremy Levin, about the big picture of biotech - and how it affects us all. They discuss the challenges facing the industry today: from global pandemics to funding cuts, to politics influencing innovation - and what it means for the future of health in the US. Dr. Levin’s book is, “Biotech in the Balance: Saving a Strategic Industry in an Age of Distrust”
Episode 683: Episode 26-26 Some People Are Just Anointed !!!
July 01, 2026
On this week’s Tech Nation, UC Berkeley Business and Entrepreneurship Professor, Dr. Toby Stuart, has studied the "Anointed" – those people who seem to get all the "good stuff". You'll learn how to recognise it. His book is “Anointed … The Extraordinary Effects of Social Status in a Winner-Take-Most World”.
Episode 682: Episode 26-25 Why Good Companies Go Bad
June 25, 2026
On this week’s Tech Nation, what sets a great company apart from the rest? Moira speaks with Eric Ries about his book, “Incorruptible: Why Good Companies Go Bad and How Great Companies Stay Great”. Then, Dr. Steve Harr tells us how Sana Biotechnology is working to engineer insulin-producing cells for Type I diabetics, without the need for immunosuppressant drugs.
Try us risk free with a FREE 3 days trial.
Join hundreds of PR teams using Podseeker to pitch and land bookings